Head-To-Head Review: MetLife (MET) & Its Peers
MetLife (NYSE: MET) is one of 29 public companies in the “Life & Health Insurance” industry, but how does it contrast to its competitors? We will compare MetLife to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.
This table compares MetLife and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
MetLife has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, MetLife’s competitors have a beta of 1.29, suggesting that their average share price is 29% more volatile than the S&P 500.
Valuation and Earnings
This table compares MetLife and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|MetLife||$63.21 billion||$817.50 million||585.84|
|MetLife Competitors||$28.59 billion||$2.35 billion||53.43|
MetLife has higher revenue, but lower earnings than its competitors. MetLife is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
MetLife pays an annual dividend of $1.60 per share and has a dividend yield of 3.0%. MetLife pays out 1,778.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Life & Health Insurance” companies pay a dividend yield of 2.2% and pay out 35.9% of their earnings in the form of a dividend. MetLife has raised its dividend for 4 consecutive years.
This is a summary of recent recommendations for MetLife and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MetLife currently has a consensus target price of $58.24, suggesting a potential upside of 10.46%. As a group, “Life & Health Insurance” companies have a potential upside of 7.20%. Given MetLife’s higher probable upside, analysts clearly believe MetLife is more favorable than its competitors.
Insider and Institutional Ownership
74.3% of MetLife shares are held by institutional investors. Comparatively, 68.4% of shares of all “Life & Health Insurance” companies are held by institutional investors. 0.3% of MetLife shares are held by insiders. Comparatively, 9.6% of shares of all “Life & Health Insurance” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MetLife competitors beat MetLife on 9 of the 15 factors compared.
MetLife Company Profile
MetLife, Inc. is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses. Its Asia segment offers products, including life insurance; accident and health insurance, and retirement and savings products. Latin America offers products, including life insurance, and retirement and savings products. Life insurance includes universal, variable and term life products. EMEA offers products, including life insurance, accident and health insurance, retirement and savings products, and credit insurance.
Receive News & Ratings for MetLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.